Published in Met Based Drugs on January 01, 2008
Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide. Blood (2012) 1.66
Targeting metabolism with arsenic trioxide and dichloroacetate in breast cancer cells. Mol Cancer (2011) 1.10
Genetic basis of arsenite and cadmium tolerance in Saccharomyces cerevisiae. BMC Genomics (2009) 1.07
High-throughput Giardia lamblia viability assay using bioluminescent ATP content measurements. Antimicrob Agents Chemother (2010) 1.05
Inhibitor of kappaB kinase beta regulates redox homeostasis by controlling the constitutive levels of glutathione. Mol Pharmacol (2010) 0.90
Posttranslational modification of human glyoxalase 1 indicates redox-dependent regulation. PLoS One (2010) 0.89
Candidate single nucleotide polymorphism markers for arsenic responsiveness of protein targets. Bioinform Biol Insights (2010) 0.85
Genomic analysis of stress response against arsenic in Caenorhabditis elegans. PLoS One (2013) 0.83
Mitochondrial proteomics of nasopharyngeal carcinoma metastasis. BMC Med Genomics (2012) 0.82
Discovery of novel antigiardiasis drug candidates. Antimicrob Agents Chemother (2014) 0.81
Enhancement of arsenic trioxide cytotoxicity by dietary isothiocyanates in human leukemic cells via a reactive oxygen species-dependent mechanism. Leuk Res (2009) 0.81
Synergistic Apoptosis-Inducing Antileukemic Effects of Arsenic Trioxide and Mucuna macrocarpa Stem Extract in Human Leukemic Cells via a Reactive Oxygen Species-Dependent Mechanism. Evid Based Complement Alternat Med (2011) 0.81
Hitting the Bull's-Eye in Metastatic Cancers-NSAIDs Elevate ROS in Mitochondria, Inducing Malignant Cell Death. Pharmaceuticals (Basel) (2015) 0.79
Robust structure and reactivity of aqueous arsenous acid-platinum(II) anticancer complexes. Angew Chem Int Ed Engl (2013) 0.78
Metalloid compounds as drugs. Res Pharm Sci (2013) 0.78
Remodulation of central carbon metabolic pathway in response to arsenite exposure in Rhodococcus sp. strain NAU-1. Microb Biotechnol (2012) 0.78
Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact (2006) 10.64
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood (1997) 4.78
Imaging dynamic redox changes in mammalian cells with green fluorescent protein indicators. J Biol Chem (2004) 4.75
Mitochondrial metabolism of reactive oxygen species. Biochemistry (Mosc) (2005) 3.92
Mechanisms of action of arsenic trioxide. Cancer Res (2002) 3.68
Arsenic toxicity and potential mechanisms of action. Toxicol Lett (2002) 3.18
Fundamental concepts of the angiogenic process. Curr Mol Med (2003) 3.16
VDAC-dependent permeabilization of the outer mitochondrial membrane by superoxide induces rapid and massive cytochrome c release. J Cell Biol (2001) 2.80
Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst (1998) 2.75
Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci U S A (1997) 2.54
The thioredoxin system in cancer. Semin Cancer Biol (2006) 2.42
Monomethylarsonous acid (MMA(III)) is more toxic than arsenite in Chang human hepatocytes. Toxicol Appl Pharmacol (2000) 2.41
Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood (2005) 2.23
Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem (2003) 2.19
Arsenic (+3 oxidation state) methyltransferase and the methylation of arsenicals. Exp Biol Med (Maywood) (2007) 2.18
The cellular metabolism and systemic toxicity of arsenic. Toxicol Appl Pharmacol (2001) 2.15
Peroxiredoxin III, a mitochondrion-specific peroxidase, regulates apoptotic signaling by mitochondria. J Biol Chem (2004) 2.14
Thioredoxin-2 inhibits mitochondria-located ASK1-mediated apoptosis in a JNK-independent manner. Circ Res (2004) 2.05
Thiol-based mechanisms of the thioredoxin and glutaredoxin systems: implications for diseases in the cardiovascular system. Am J Physiol Heart Circ Physiol (2006) 1.99
The theory of APL revisited. Curr Top Microbiol Immunol (2007) 1.96
High-throughput identification of catalytic redox-active cysteine residues. Science (2007) 1.92
A new metabolic pathway of arsenite: arsenic-glutathione complexes are substrates for human arsenic methyltransferase Cyt19. Arch Toxicol (2004) 1.88
Modulation of the mitochondrial permeability transition pore by pyridine nucleotides and dithiol oxidation at two separate sites. J Biol Chem (1996) 1.85
Role of critical thiol groups on the matrix surface of the adenine nucleotide translocase in the mechanism of the mitochondrial permeability transition pore. Biochem J (2002) 1.85
Monomethylarsonous acid (MMA(III)) and arsenite: LD(50) in hamsters and in vitro inhibition of pyruvate dehydrogenase. Chem Res Toxicol (2001) 1.72
The role of arsenic-thiol interactions in metalloregulation of the ars operon. J Biol Chem (1996) 1.69
Essential role of the voltage-dependent anion channel (VDAC) in mitochondrial permeability transition pore opening and cytochrome c release induced by arsenic trioxide. Oncogene (2004) 1.57
Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1). Evidence that a tri-glutathione conjugate is required. J Biol Chem (2004) 1.52
Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol (2005) 1.51
Biomarkers of exposure: a case study with inorganic arsenic. Environ Health Perspect (2006) 1.51
A comparison of arsenate and vanadate as inhibitors or uncouplers of mitochondrial and glycolytic energy metabolism. Biochemistry (1973) 1.50
Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis. Mol Cancer Res (2003) 1.47
Introduction: the history of arsenic trioxide in cancer therapy. Oncologist (2001) 1.46
Oxidation of a critical thiol residue of the adenine nucleotide translocator enforces Bcl-2-independent permeability transition pore opening and apoptosis. Oncogene (2000) 1.45
Differential oxidation of thioredoxin-1, thioredoxin-2, and glutathione by metal ions. Free Radic Biol Med (2005) 1.44
Monomethylarsonous acid induces transformation of human bladder cells. Toxicol Appl Pharmacol (2006) 1.38
Functional and molecular characterization of the human neutral solute channel aquaporin-9. Am J Physiol (1999) 1.37
Identity and functions of CxxC-derived motifs. Biochemistry (2003) 1.37
Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore. Exp Cell Res (1999) 1.33
Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood (2002) 1.32
Methylated arsenicals: the implications of metabolism and carcinogenicity studies in rodents to human risk assessment. Crit Rev Toxicol (2006) 1.27
Purine nucleoside phosphorylase as a cytosolic arsenate reductase. Toxicol Sci (2002) 1.25
Role of MRP2 and GSH in intrahepatic cycling of toxins. Toxicology (2001) 1.22
Relations between structure and function of the mitochondrial ADP/ATP carrier. Annu Rev Biochem (2006) 1.22
Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by lonidamine, arsenite and CD437. Oncogene (2001) 1.22
Arsenic trioxide uptake by human and rat aquaglyceroporins. Biochem Biophys Res Commun (2004) 1.21
Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner. Blood (1998) 1.20
Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells. Blood (2006) 1.19
Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies. Curr Opin Hematol (2005) 1.13
Synthesis and hydrolysis of ADP-arsenate by beef heart submitochondrial particles. J Biol Chem (1983) 1.11
Contribution of the translocator of adenine nucleotides and the ATP synthase to the control of oxidative phosphorylation and arsenylation in liver mitochondria. J Biol Chem (1985) 1.11
Mitogenic signal transduction caused by monomethylarsonous acid in human bladder cells: role in arsenic-induced carcinogenesis. Toxicol Sci (2006) 1.11
Trivalent arsenicals induce lipid peroxidation, protein carbonylation, and oxidative DNA damage in human urothelial cells. Mutat Res (2006) 1.10
Glutathione S-transferase pi facilitates the excretion of arsenic from arsenic-resistant Chinese hamster ovary cells. Biochem Biophys Res Commun (1993) 1.10
Uptake of inorganic and organic derivatives of arsenic associated with induced cytotoxic and genotoxic effects in Chinese hamster ovary (CHO) cells. Toxicol Appl Pharmacol (2004) 1.08
Trace element speciation in poultry litter. J Environ Qual (2003) 1.06
Dynamic evolution of the adenine nucleotide translocase interactome during chemotherapy-induced apoptosis. Oncogene (2004) 1.05
Equilibrium characterization of the As(III)-cysteine and the As(III)-glutathione systems in aqueous solution. J Inorg Biochem (2004) 1.05
A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells. Cancer Cell (2003) 1.03
Arsenite and monomethylarsonous acid generate oxidative stress response in human bladder cell culture. Toxicol Appl Pharmacol (2006) 1.03
Reactive oxygen species are involved in arsenic trioxide inhibition of pyruvate dehydrogenase activity. Chem Res Toxicol (2003) 1.03
Control of cellular proliferation by modulation of oxidative phosphorylation in human and rodent fast-growing tumor cells. Toxicol Appl Pharmacol (2006) 1.02
Formation and urinary excretion of arsenic triglutathione and methylarsenic diglutathione. Chem Res Toxicol (2004) 1.01
Molecular, functional, and pathological aspects of the mitochondrial ADP/ATP carrier. Physiology (Bethesda) (2006) 1.01
Covalent modification and active site-directed inactivation of a low molecular weight phosphotyrosyl protein phosphatase. Biochemistry (1992) 0.99
Intracellular interaction and metabolic fate of arsenite and arsenate in mice and rabbits. Chem Biol Interact (1983) 0.99
Arsenic in cancer therapy. Anticancer Drugs (2005) 0.98
Isolation and characterization of the discrete N- and C-terminal halves of rat brain hexokinase: retention of full catalytic activity in the isolated C-terminal half. Arch Biochem Biophys (1989) 0.97
Thiol-modifying phenylarsine oxide inhibits guanine nucleotide binding of Rho but not of Rac GTPases. Mol Pharmacol (2003) 0.95
Protective effects of hepatocellular canalicular conjugate export pump (Mrp2) on sodium arsenite-induced hepatic dysfunction in rats. Exp Toxicol Pathol (2007) 0.94
Inhibition of coupling factor B activity by cadmium ion, arsenite-2,3-dimercaptopropanol, and phenylarsine oxide, and preferential reactivation by dithiols. J Biol Chem (1981) 0.93
Factor B and the mitochondrial ATP synthase complex. J Biol Chem (2001) 0.93
Distinct gene expression profiles in immortalized human urothelial cells exposed to inorganic arsenite and its methylated trivalent metabolites. Environ Health Perspect (2006) 0.92
Reactions of lipoamide dehydrogenase and glutathione reductase with arsonic acids and arsonous acids. Arch Biochem Biophys (1985) 0.91
Thioarsenates in sulfidic waters. Environ Sci Technol (2005) 0.91
Toxicity of a trivalent organic arsenic compound, dimethylarsinous glutathione in a rat liver cell line (TRL 1215). Br J Pharmacol (2006) 0.91
Glutathione-S-transferase-omega [MMA(V) reductase] knockout mice: enzyme and arsenic species concentrations in tissues after arsenate administration. Toxicol Appl Pharmacol (2006) 0.91
Bovine factor B: cloning, expression, and characterization. Arch Biochem Biophys (2006) 0.90
Transfer of O18 in arsenolysis reactions. J Biol Chem (1960) 0.90
Inhibition of pyruvate dehydrogenase multienzyme complex from Escherichia coli with a radiolabeled bifunctional arsenoxide: evidence for an essential histidine residue at the active site of lipoamide dehydrogenase. Biochemistry (1984) 0.90
Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent. Curr Med Res Opin (2005) 0.89
Mitocans: mitochondrial targeted anti-cancer drugs as improved therapies and related patent documents. Recent Pat Anticancer Drug Discov (2006) 0.89
The dynamic dimerization of the yeast ADP/ATP carrier in the inner mitochondrial membrane is affected by conserved cysteine residues. J Biol Chem (2003) 0.89
Factor B is essential for ATP synthesis by mitochondria. Arch Biochem Biophys (2002) 0.89
A broad view of arsenic. Poult Sci (2007) 0.89
Chronic exposure to methylated arsenicals stimulates arsenic excretion pathways and induces arsenic tolerance in rat liver cells. Toxicol Sci (2006) 0.88
Inorganic arsenic in drinking water: an evolving public health concern. J Natl Cancer Inst (2007) 0.88
Glutathione-S-transferase pi inhibits As2O3-induced apoptosis in lymphoma cells: involvement of hydrogen peroxide catabolism. Blood (2004) 0.88
MRP2 and acquired tolerance to inorganic arsenic in the kidney of killifish (Fundulus heteroclitus). Toxicol Sci (2007) 0.87
The glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase works as an arsenate reductase in human red blood cells and rat liver cytosol. Toxicol Sci (2005) 0.87
Indirect effects of Bax and Bak initiate the mitochondrial alterations that lead to cytochrome c release during arsenic trioxide-induced apoptosis. Cancer Biol Ther (2005) 0.86
Mechanism of selectivity of an angiogenesis inhibitor from screening a genome-wide set of Saccharomyces cerevisiae deletion strains. J Natl Cancer Inst (2005) 0.86
Voltage-dependent anion channel proteins in synaptosomes of the torpedo electric organ: immunolocalization, purification, and characterization. J Bioenerg Biomembr (1998) 0.85
Energy-linked binding of Pi is required for continuous steady-state proton-translocating ATP hydrolysis catalyzed by F0.F1 ATP synthase. Biochemistry (2006) 0.85
Stability of arsenic metabolites, arsenic triglutathione [As(GS)3] and methylarsenic diglutathione [CH3As(GS)2], in rat bile. Toxicology (2005) 0.84
Interaction of phosphate analogues with glyceraldehyde-3-phosphate dehydrogenase. Biochemistry (1979) 0.82
Glutathione-dependent reduction of arsenate in human erythrocytes--a process independent of purine nucleoside phosphorylase. Toxicol Sci (2004) 0.82
Preventive mechanism of cellular glutathione in monomethylarsonic acid-induced cytolethality. Toxicol Appl Pharmacol (2004) 0.82